Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTX-106
- Development stage
- Preclinical
- Lead developer
- Providence Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
PTX-106 is a personalized mRNA-based cancer vaccine developed by Providence Therapeutics. It utilizes the company's proprietary mRNA platform to encode neoantigens specific to an individual patient's tumor, identified through genomic sequencing. The vaccine is designed to prime and expand the patient's T-cell repertoire to recognize and eliminate cancer cells expressing these unique mutations. This personalized approach aims to overcome the limitations of 'off-the-shelf' therapies by targeting the specific mutational landscape of each malignancy. PTX-106 is currently in the IND-enabling (Pre-IND) stage of development for personalized cancer treatment.
- Other names
- PTX-106 mRNA vaccinePTX106 mRNA vaccinePTX 106 mRNA vaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on PTX-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTX-106.